Entry Point Capital, LLC Exelixis, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 8,433 shares of EXEL stock, worth $295,155. This represents 0.13% of its overall portfolio holdings.
Number of Shares
8,433
Previous 18,663
54.81%
Holding current value
$295,155
Previous $484,000
42.15%
% of portfolio
0.13%
Previous 0.28%
Shares
4 transactions
Others Institutions Holding EXEL
# of Institutions
569Shares Held
249MCall Options Held
1.72MPut Options Held
1.54M-
Black Rock Inc. New York, NY33.5MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.03 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$820 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$535 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$399 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...